Fluticasone Furoate Chemical Structure (Arnuityellipta Spl Graphic 01)
Arnuity Ellipta Powder
Product Images NDC 0173-0876
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Arnuity Ellipta (NDC 0173-0876). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1. Impact Of Intrinsic Factors On The Pharmacokinetics (pk) Of Fluticasone Furoate (ff) (Arnuityellipta Spl Graphic 02)
Figure 2. Impact Of Coadministered Ketoconazolea On The Pharmacokinetics (pk) Of Fluticasone Furoate (Arnuityellipta Spl Graphic 03)
This text seems to be a table displaying the impact of extrinsic factors on Fluticasone Furoate PK (pharmacokinetics) with respect to an interacting drug. The table lists fold changes and 90% confidence intervals of Fluticasone Furoate's area under the curve (AuC) and maximum concentration (Cmax) in response to different dosages of the interacting drug. The only drug mentioned here is "Ketoconazole" which seems to reduce Fluticasone Furoate's AuC and Cmax. The table recommends caution while prescribing Fluticasone Furoate in conjunction with Ketoconazole.*
Figure 3. Dose-ranging Trials (Arnuityellipta Spl Graphic 04)
Figure 4. Mean Change From Baseline In Individual Serial Fev1 (ml) Assessments After 12 Weeks Of Treatment – Trial 2 (Arnuityellipta Spl Graphic 05)
This is a table displaying LS Mean Change from Baseline (measured in mL) and Planned Time since Dose (measured in hours) for ARNUITY ELLIPTA 100 mcg once daily and Placebo. The values for LS Mean Change from Baseline are 70, 500, 0, 300, 20, and 100. The values for Planned Time since Dose are not specified.*
Figure 5. Mean Change From Baseline In Trough Fev1 (ml) Over Time – Trial 3 (Arnuityellipta Spl Graphic 06)
Figure 6. Mean Change From Baseline In Individual Serial Fev1 (ml) Assessments After 24 Weeks Of Treatment – Trial 4 (Arnuityellipta Spl Graphic 07)
Parts Figure (Arnuityellipta Spl Graphic 08)
Pil Figure A (Arnuityellipta Spl Graphic 09)
Pil Figure B (Arnuityellipta Spl Graphic 10)
Pil Figure C (Arnuityellipta Spl Graphic 11)
Pil Figure D (Arnuityellipta Spl Graphic 12)
Pil Figure E (Arnuityellipta Spl Graphic 13)
Pil Figure F (Arnuityellipta Spl Graphic 14)
Pil Figure G (Arnuityellipta Spl Graphic 15)
Pil Figure H (Arnuityellipta Spl Graphic 16)
Pil Figure I (Arnuityellipta Spl Graphic 17)
Pil Figure J (Arnuityellipta Spl Graphic 18)
Pil Figure K (Arnuityellipta Spl Graphic 19)
Pil Figure L (Arnuityellipta Spl Graphic 20)
Arnuity Ellipta 100mcg 30 Count Carton (Arnuityellipta Spl Graphic 21)
This is a medication called Arnuity Ellipta, which is a powder that is inhaled orally for treating breathing problems. Each blister pack contains 50mcg of the active ingredient, Fluticasone Furoate, along with lactose monohydrate. The National Drug Code (NDC) for this medication is 0173-0888-10.*
Arnuity Ellipta 200mcg 30 Count Carton (Arnuityellipta Spl Graphic 22)
The text describes a medication called ANNUITY ELLIPTA, with the NDC code of 0173-0874-10. It is a prescription medication that contains fluticasone furoate inhalation powder and lactose monohydrate, which is used for oral inhalation only. Each blister pack contains 100 micrograms of the medication.*
Arnuityellipta Spl Graphic 23
This text is a label for medication. The medication is called "Fluticasone Furoate Inhalation Powder" and comes in a package with the trade name "N UITY ELLIPTA". It is intended for oral inhalation only and contains 200 mcg of fluticasone furoate and lactose monohydrate per blister. The package is only available with a prescription (Rx Only).*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
